× Medicines Discovery Catapult

Keeping secrets in drug discovery

SMEs in the life sciences sector are the lifeblood of new innovations. If that’s you, it means that some of your most valuable assets will be your intellectual property and know-how. Most likely, you will have inventions which you are looking to patent, and other key confidential information. Inventions It is important to keep your […]

Read more

Putting the human back into medicines discovery

Is there something missing from your research? The need to humanise drug discovery was highlighted in the State of the Discovery Nation report. This is not surprising given that from the 63% of drugs that pass Phase I safety, only 31% pass Phase II human proof of concept and only 50% pass on through Phase […]

Read more

Biotech faces brighter, if more complex future

The world’s biotech community came together at BIO in San Diego last week. And, above the usual clamour of countries competing to promote their sectors – and their national cultures and delicacies (the Czech Republic even had a folk singer in national costume!) – I heard three big themes, each of which makes life more complex […]

Read more

The importance of collaboration

A guest blog from Aisling Burnand, CEO of The Association of Medical Research Charities Collaboration can make all the difference to patients and their loved ones, and we need to work together to make it happen. I see collaboration as a powerful antidote to the challenges and barriers that face all of us in the […]

Read more

Catapult open for business to support UK drug discovery

New £1m facilities at University of Warwick open to support collaborative drug discovery, announces CEO Chris Molloy I am five months into my job as Chief Executive of the Medicines Discovery Catapult and I am delighted to be able to say we are now well and truly open for business to support and promote innovative, […]

Read more

The Time is Now!

CEO Chris Molloy celebrates 100 days at the Medicines Discovery Catapult It is 100 days since I started as CEO of the Medicines Discovery Catapult.  Every day since, engagement with the broad UK Medicines community has increased my certainty of being able to deliver unique help, enabling them to get better medicines to patients faster. By taking advantage […]

Read more

We don’t know everything, but we are not completely in the dark

Board Member Peter Kellner writes about the role of the Medicines Discovery Catapult and the importance of collaboration post-Brexit  Britain’s long-term prospects, post-Brexit, will plainly be affected by our trading arrangements with the rest of Europe and the wider world. The full impact may not be clear for some years. But, as this week’s industrial […]

Read more

A new approach for 2017

As 2017 begins, we are looking forward to new beginnings, new ways of thinking and new approaches to medicines discovery. 2016 was an eventful year across the globe, and changes in the political landscape will undoubtedly affect the biopharma industry, creating an atmosphere of inevitable uncertainty. On the bright side, though, investment in Life Sciences […]

Read more

A problem shared…

CEO Chris Molloy explains why collaboration is essential to the discovery of new and effective medicines. As 2016 ends, we are looking forward to an exciting New Year at the Medicines Discovery Catapult (MDC). We are building new facilities, investing in cutting edge equipment, attracting talented people and planning impactful projects as we begin our […]

Read more

Science & Technology

Informatics

Virtual R&D

Discovery Syndicates

Samples and Data